{
    "clinical_study": {
        "@rank": "8227", 
        "arm_group": [
            {
                "arm_group_label": "EE20/DRSP(BAY86-5300)-flexibel extended regimen", 
                "arm_group_type": "Experimental", 
                "description": "One tablet  [0.02 mg of ethinylestradiol (\u03b2-CDC) and 3 mg of drospirenone] / day with flexible extended regimen (24-day to 120-day active tablet intake followed by 4-day tablet free interval)"
            }, 
            {
                "arm_group_label": "EE20/DRSP(BAY86-5300)-28 days cyclic regimen", 
                "arm_group_type": "Active Comparator", 
                "description": "One tablet  [0.02 mg of ethinylestradiol (\u03b2-CDC) and 3 mg of drospirenone] / day with 28-day cyclic regimen (24-day active tablet intake followed by 4-day placebo tablet intake)"
            }
        ], 
        "brief_summary": {
            "textblock": "The is a multi-center, randomized, open-label, active-controlled, parallel-group comparative\n      study (24-week treatment period).\n\n      The objective of this study is to prove the superiority of BAY 86-5300 with flexible\n      extended regimen for treatment of dysmenorrhea to BAY 86-5300 with 28-day cyclic regimen in\n      terms of primary efficacy variable, number of days with dysmenorrheic pain over 140 days of\n      evaluation period.\n\n      In addition, the long-term safety of the flexible extended regimen of BAY86-5300 in patients\n      treated for one year will be investigated."
        }, 
        "brief_title": "Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Dysmenorrhea", 
        "condition_browse": {
            "mesh_term": "Dysmenorrhea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria: - Dysmenorrhea patients with a total dysmenorrhea score (sum of the\n        two sub-scores: severity of dysmenorrhea and use of analgesics) of at least 3 points in\n        each of the last two menstruations before randomization (baseline observation phase)\n\n          -  Patients with dysmenorrheic pain during the 2 baseline cycles before randomization.\n             Dysmenorrheic pain means any spasmodic pelvic pain or lower abdominal pain with\n             possible radiation towards back or thighs recorded in the Patient Diary in\n             correspondence with a withdrawal and/or menstrual bleeding episode.  Pain could start\n             up to 2 days before the onset of the bleeding episode the bleeding and terminates on\n             the last day of bleeding of before\n\n          -  Patients having the regular cyclic menstrual period (25 to 38 days) in the latest two\n             menses before randomization (baseline observation phase)\n\n          -  Willingness to use a barrier method (i.e., non-hormonal method) for contraception\n             during the study. Acceptable methods of contraception include (i) condoms (male or\n             female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with\n             spermicide; (iii) intra-uterine device.\n\n        Exclusion Criteria: - Patients who have organic diseases of which surgical treatment is\n        prioritized by the investigator\n\n          -  Patients aged 40 years or older with ovarian chocolate cysts being more than 10 cm in\n             size of the longest diameters\n\n          -  Patients with ovarian chocolate cysts having solid part in the cyst\n\n          -  Patients for whom YAZ Combination Tablet is contraindicated (according to Japanese\n             Labeling)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "204", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892904", 
            "org_study_id": "16114"
        }, 
        "intervention": {
            "arm_group_label": [
                "EE20/DRSP(BAY86-5300)-flexibel extended regimen", 
                "EE20/DRSP(BAY86-5300)-28 days cyclic regimen"
            ], 
            "description": "One tablet  [0.02 mg of ethinylestradiol (\u03b2-CDC) and 3 mg of drospirenone] / day", 
            "intervention_name": "EE20/DRSP(BAY86-5300)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ethinyl Estradiol", 
                "Drospirenone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "YAZ", 
            "Flexible regimen", 
            "Drospirenone", 
            "Ethinylestradiol Betadex", 
            "Dysmenorrhea", 
            "Japanese patients"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Matsudo", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "270-2267"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hachioji", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "192-0046"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minato", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "108-0071"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Setagaya-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "157-0066"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suginami-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "167-0051"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toshima-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "171-0021"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "542-0086"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "530-0013"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-center, Randomized, Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of a Flexible Extended Regimen of BAY 86-5300 (0.02 mg Ethinylestradiol [\u03b2-CDC] and 3 mg Drospirenone) Compared to the 28-day (24 + 4-day) Regimen of BAY 86-5300 in the Treatment of Dysmenorrhea for 24 Weeks", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of days with dysmenorrheic pain is determined based on daily record of Patient Diary.", 
            "measure": "Number of days with dysmenorrheic pain over 140 days of evaluation period", 
            "safety_issue": "No", 
            "time_frame": "Evaluation period which starts on 25th day after start of treatment and lasts for 140 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892904"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Dysmenorrhea score is a sum of the two sub-scores, severity of dysmenorrhea and use of analgesics, recorded by the participant at every visit", 
                "measure": "Change in Dysmenorrhea score from baseline to period of withdrawal bleeding", 
                "safety_issue": "No", 
                "time_frame": "Baseline period (8 weeks before start of treatment) and evaluation period which  starts on 25th day after start of treatment and lasts for 140 days"
            }, 
            {
                "description": "The severity of pain is measured by the Visual Analogue Scale (VAS), recorded by the participant at any visit.", 
                "measure": "Change of severity of pain Description", 
                "safety_issue": "No", 
                "time_frame": "Baseline period (8 weeks before start of treatment) and evaluation period which  starts on 25th day after start of treatment and lasts for 140 days"
            }, 
            {
                "description": "Number of days with at least moderate dysmenorrheic pain is determined based on daily record of Patient Diary.", 
                "measure": "Number of days with at least moderate dysmenorrheic pain over 140 days of evaluation period", 
                "safety_issue": "No", 
                "time_frame": "Evaluation period which starts on 25th day after start of treatment and lasts for 140 days"
            }, 
            {
                "description": "Number of days with rescue medicine is determined based on daily record of Patient Diary.", 
                "measure": "Number of days with rescue medicine used for relief of dysmenorrhea or pelvic pain over 140 days of evaluation period", 
                "safety_issue": "No", 
                "time_frame": "Evaluation period which  starts on 25th day after start of treatment and lasts for 140 days"
            }, 
            {
                "description": "Number of days with interference of dysmenorrheic pain with daily activity is determined based on daily record of Patient Diary", 
                "measure": "Number of days with interference of dysmenorrheic pain with daily activity over 140 days of evaluation period", 
                "safety_issue": "No", 
                "time_frame": "Evaluation period which  starts on 25th day after start of treatment and lasts for 140 days"
            }, 
            {
                "description": "Endometrial thickness is the thickest value (mm) of endometrium determined by transvaginal ultrasonography.", 
                "measure": "Endometrial thickness", 
                "safety_issue": "No", 
                "time_frame": "24 weeks after taking the initial study medication"
            }, 
            {
                "description": "Number of days with spotting/bleeding is determined based on daily record of Patient Diary.", 
                "measure": "Number of days with bleeding and spotting over treatment phase", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}